Comparative Pharmacology
Head-to-head clinical analysis: ACYLANID versus LANOXIN PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYLANID versus LANOXIN PEDIATRIC.
ACYLANID vs LANOXIN PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acylanid is a cardiac glycoside that inhibits the Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium concentrations, which enhances myocardial contractility.
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
0.1 mg IV bolus over 5 minutes, followed by 0.1 mg IV after 1 hour if needed; then 0.1-0.2 mg orally every 6-8 hours for maintenance. Maximum cumulative dose: 0.4 mg IV.
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
None Documented
None Documented
Terminal half-life 33–36 hours (anuric patients up to 110 hours); requires dose adjustment in renal impairment.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Renal (≈70% as unchanged drug), biliary/fecal (≈30%)
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside